Apr 28 2011
AquaStar Holdings, Inc. (Pink Sheets: RPPR) is pleased to announce that the United States Patent and Trademark Office has issued patent number 7,708,944 for the Ultra-Sensitive, Portable Capillary Sensor technology utilized by the Capwave Enzyme-Linked Immuno-Sorbent Assay (ELISA) platform.
The patent, entitled "Ultra-Sensitive, Portable Capillary Sensor" details research completed at the State University of New York Binghamton supported in part by grants from the United States Environmental Protection Agency and IEEC/National Science Foundation. The patent method is the essence of the rapid, sensitive, and portable Enzyme-Linked ImmunoSorbent Assay (ELISA) platform Capwave technology, which enables the user to quickly detect Bioweapons (anthrax, bacillus globigii), Biomarkers (cancer, stem cells), Toxins (E. coli and salmonella in foodborne illness), Contaminants and Diseases (both viral and bacterial).
"We are very pleased with the progress being made toward the commercial offering of the Capwave technology. Obviously, gaining protection for the intellectual property is an important step in the process," stated Malcolm Lennie, President of AquaStar Holdings, Inc.
In further news, the Company recently announced that its client's Capwave licensed technology has received over $600,000 in federal research grants from the U.S. Government. The State University of New York (SUNY) Binghamton has confirmed that the U.S. Army Research Office, the U.S. Army Research Development & Engineering Command, the EPA and the National Research Council have contributed over $618,000 in total funding to benefit the Research and Development of Capwave's portable Enzyme-Linked Immuno-Sorbent Assay (ELISA) platform technology.
How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics